AlphaCentric Advisors’s Fulgent Genetics FLGT Stock Holding History

AlphaCentric Advisors’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-39,000	Closed	-$1.44M	–	246
2023 Q2	$1.44M	Sell	39,000 -500	-1%	-$17.4K	0.8%	45
2023 Q1	$1.23M	Hold	39,500	–	–	0.85%	35
2022 Q4	$1.18M	Buy	39,500 +9,000	+30%	+$322K	1.16%	24
2022 Q3	$1.16M	Buy	+30,500	New	+$1.53M	1.19%	20

Other funds holding FLGT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DSCM

Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

AlphaCentric Advisors's FLGT Position: Q3 2023 in Review

AlphaCentric Advisors sold out of Fulgent Genetics (FLGT) in Q3 2023, closing a stake of 39,000 shares — an estimated $1.44M sold.

AlphaCentric Advisors first reported a position in FLGT in Q3 2022 and held it in 4 quarters. The position peaked at $1.44M in Q2 2023. 201 funds tracked by Wall St. Rank hold FLGT as of Q3 2023.

AlphaCentric Advisors reported no remaining Fulgent Genetics position as of Q3 2023 after selling out during the quarter.
AlphaCentric Advisors sold 39,000 Fulgent Genetics shares in Q3 2023, an estimated $1.44M.
AlphaCentric Advisors first reported a position in Fulgent Genetics in Q3 2022 and held it in 4 quarters.
AlphaCentric Advisors's Fulgent Genetics position peaked at $1.44M in Q2 2023.
201 funds tracked by Wall St. Rank held Fulgent Genetics as of Q3 2023.

Based on AlphaCentric Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.